Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies.
Neuronal inclusions comprised of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease - the most prevalent tauopathy - misfolded tau is probably a key pathological agent. The recent failure of amyloid-beta-targeted therapeutics in Phase III clinical trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease. Here, we focus on strategies directed at reducing misfolded tau and compensating for the loss of normal tau function.
Center for Neurodegenerative Disease Research, Institute on Aging, Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104-4283, USA. kbrunden@upenn.edu
Kurt R
KR
Brunden
John Q
JQ
Trojanowski
Virginia M-Y
VM
Lee
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000818:Animals; D055808:Drug Discovery / Q000379:methods / Q000639:trends*; D006801:Humans; D024801:Tauopathies / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016875:tau Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism
D016875:tau Proteins